Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: Results from Two Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trials

被引：0
|
作者：
Silverberg, Jonathan [1 ]
Thaci, Diamant [2 ]
Seneschal, Julien [3 ,4 ]
Gold, Linda Stein [5 ]
Blauvelt, Andrew [6 ]
Simpson, Eric [7 ]
Chu, Chia-Yu [8 ,9 ]
Liu, Zhuqing [10 ]
Lima, Renata Gontijo [10 ]
Pillai, Sreekumar [10 ]
Guttman-Yassky, Emma [11 ]
机构：
[1] George Washington Univ, Sch Med, Washington, DC USA
[2] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany
[3] Univ Bordeaux, Bordeaux, France
[4] Hosp St Andre, Natl Reference Ctr Rare Skin Disorders, Bordeaux, France
[5] Henry Ford Hlth Syst, Detroit, MI USA
[6] Oregon Med Res Ctr, Portland, OR USA
[7] Oregon Hlth & Sci Univ, Portland, OR USA
[8] Natl Taiwan Univ Hosp, Taipei, Taiwan
[9] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[10] Eli Lilly & Co, Indianapolis, IN USA
[11] Icahn Sch Med Mt Sinai, New York, NY USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P075
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [31] Bimekizumab efficacy and safety in Korean patients with moderate to severe plaque psoriasis: A phase 3, randomized, placebo-controlled, double-blinded study
    Youn, Sang Woong
    Jo, Seong Jin
    Park, Chul Jong
    Kim, Dong Hyun
    Shin, Bong Seok
    Jeong, Ki Heon
    Bang, Chul Hwan
    Cross, Nancy
    Thirlwell, Jackie
    Hoepken, Bengt
    JOURNAL OF DERMATOLOGY, 2024, 51 (11): : 1392 - 1403
  • [32] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
    Katoh, Norito
    Tanaka, Akio
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Igawa, Ken
    CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
  • [33] <show/>Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials<show/>
    Yosipovitch, Gil
    Lio, Peter A.
    Rosmarin, David
    Serra-Baldrich, Esther
    Legat, Franz J.
    Casillas, Marta
    Pierce, Evangeline
    Liu, Zhuqing
    Sun, Luna
    Elmaraghy, Hany
    Staender, Sonja
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (02) : 289 - 291
  • [34] Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials
    Zirwas, Matthew J.
    Boguniewicz, Mark
    Rosmarin, David
    Fuxench, Zelma Chiesa
    Warren, Richard B.
    Torres, Tiago
    de Bruin-Weller, Marjolein
    Dawson, Zach
    Atwater, Amber Reck
    Elmaraghy, Hany
    Pierce, Evangeline
    Bardolet, Laia
    Zhong, Jinglin
    Armstrong, April W.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 54 - 56
  • [35] Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks
    Blauvelt, A.
    Thyssen, J. P.
    Guttman-Yassky, E.
    Bieber, T.
    Serra-Baldrich, E.
    Simspon, E.
    Rosmarin, D.
    Diemert, S.
    Elmaraghy, H.
    Silverberg, J.
    ALLERGOLOGIE, 2023, 46 (08) : 530 - 530
  • [36] Improvement of platysma prominence with onabotulinumtoxinA: Safety and efficacy results from a randomized, double-blinded, placebo-controlled phase 3 trial
    Fabi, Sabrina
    Humphrey, Shannon
    Biesman, Brian
    George, Rosalyn
    Latowsky, Brenda
    Weiss, Robert A.
    Park, Grace S.
    Shimoga, Sandhya
    Lee, Elisabeth
    Jierjian, Edward
    Tong, Warren
    Hopfinger, Rene
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (02) : 285 - 291
  • [37] Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials
    Gold, Linda Stein
    Thaci, Diamant
    Thyssen, Jacob P.
    Gooderham, Melinda
    Laquer, Vivian
    Natalie, Chitra R.
    Zhao, Fangyi
    Meskimen, Eric
    ElMaraghy, Hany
    Montmayeur, Sonia
    Jimenez, Gemma
    de Bruin-Weller, Marjolein
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [38] Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
    Paller, Amy S.
    Siegfried, Elaine C.
    Thaci, Diamant
    Wollenberg, Andreas
    Cork, Michael J.
    Arkwright, Peter D.
    Gooderham, Melinda
    Beck, Lisa A.
    Boguniewicz, Mark
    Sher, Lawrence
    Weisman, Jamie
    O'Malley, John T.
    Patel, Naimish
    Hardin, Megan
    Graham, Neil M. H.
    Ruddy, Marcella
    Sun, Xian
    Davis, John D.
    Kamal, Mohamed A.
    Khokhar, Faisal A.
    Weinreich, David M.
    Yancopoulos, George D.
    Beazley, Bethany
    Bansal, Ashish
    Shumel, Brad
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (05) : 1282 - 1293
  • [39] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [40] Lebrikizumab improvement in itch reduction at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials
    Yosipovitch, Gil
    Lio, Peter
    Rosmarin, David
    Legat, Franz
    Carrascosa, Jose Manuel
    Meskimen, Eric
    Casillas, Marta
    Pierce, Evangeline
    Liu, Zhuqing
    Zhong, Jinglin
    Staender, Sonja
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB188 - AB188
12345